← Evidence map

ArticleMolecular therapy. Oncology2026

Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses.

Latika Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses. | OpenQuestion